

PRODUCT/CATEGORY	Technology	Description	Advantages	Disadvantages
Genome/Exome	Next Generation Sequencing (NGS)	<ul> <li>Process that determines the order of nucleotides, building blocks of DNA in an individual's genetic code.</li> <li>Whole Genome Sequencing (WGS) sequences both the entire protein coding and the non-coding regions of the genome.</li> <li>Whole Exome Sequencing (WES) sequences all the protein coding regions in the genome (exons).</li> </ul>	<ul> <li>Cost-effective solution for the diagnosis of complex and unsolved cases</li> <li>Helps determine whether a couple is at risk of having a child with a genetic condition as well as prognostic information regarding the disease</li> <li>Help determine if a disease-causing variant is inherited and helping to prevent any further genetic disorder</li> <li>Faster turnaround time for high sample volumes</li> <li>Higher sensitivity to detect low-frequency variants</li> </ul>	<ul> <li>Expensive equipment</li> <li>Bioinformatic processing of data</li> <li>Less cost-effective for sequencing low numbers of targets (1-20 targets)</li> <li>Time-consuming for sequencing low number of targets (1-20 targets)</li> </ul>
2 Chromosomal Microarray (CMA)	Chromosomal Microarray (CMA)	<ul> <li>Molecular cytogenetic method for the analysis of copy number variations (CNVs)</li> <li>Gold standard for the detection of CNVs</li> </ul>	<ul> <li>Detects structural aberrations by providing information on thousands of targets in a single experiement detecting copy number changes at the gene, chromosome and genome level.</li> <li>Provides comprehensive genetic testing for the most commom chromosomal conditions as well as large number of severe genetic conditions not detected by traditional chromosome analysis.</li> </ul>	• CMA cannot detect rearrangements (i.e balanced translocations, small deletions, sequence variants, mosaicisms etc)
् Precision Panels	Next Generation Sequencing (NGS)	<ul> <li>Testing multiple genes associated with a particular disorder, thus, creating genetic panels based on WGS.</li> <li>Panels include all relevant pathogenic and likely pathogenic variants within coding regions, regulatory sequences, and deep intronic regions described in Human Gene Mutation Database (HGMD).</li> </ul>	<ul> <li>Allow the utilization of strong diagnostic hypothesis to reduce the cost while benefitting from the power and upside of WGS</li> <li>Fast, thorough, and cost-effective diagnosis for patients with distinctive clinical features</li> <li>Option of creating customed precision panels based on genetic demand of the patient</li> </ul>	<ul> <li>Expensive equipment</li> <li>Bioinformatic processing of data</li> <li>Less cost-effective for sequencing low numbers of targets (1-20 targets)</li> <li>Time-consuming for sequencing low number of targets (1-20 targets)</li> </ul>
4 Gene Analysis	Multiplex ligation-dependent probe amplification (MLPA)	<ul> <li>Multiplex PCR method that detects abnormal copy numbers of up to 50 different genomic DNA or RNA sequences associated with a disease</li> <li>MLPA can also detect DNA methylation changes (MS-MLPA)</li> </ul>	<ul> <li>Most reliable and cost-effective method to detect known deletion/duplications and specific CNVs.</li> <li>Is able to discern between point mutations, as well as duplication/deletion of genes</li> <li>Small alterations to the MLPA protocol can allow for a variety of applications</li> </ul>	<ul> <li>Is not able to detect large CNVs, sequence variants or mosaicisms</li> <li>MLPA is very sensitive to impurities</li> </ul>
	Expansion (EXP)	<ul> <li>Gold standard assessment for many repeat expansion diseases</li> <li>PCR-based screening of repeat lengths</li> </ul>	<ul> <li>Run test with fewer requirements (no controls, no size thresholds)</li> </ul>	<ul> <li>Limited to only repeat expansions</li> <li>Will eventually be substituted by WES and WGS</li> </ul>
	NGS	"		
	Sanger/MiniSeq sequencing (SANG)	<ul> <li>Also known as "chain termination methos" is a method for determining nucleotide sequences in DNA</li> </ul>	<ul> <li>Fast, cost-effective sequencing for low number of targets (1-20 targets)</li> <li>Verification sequencing for site-directed mutagenesis</li> </ul>	<ul> <li>Low sensitivity</li> <li>Low discovery power</li> <li>Not as cost-effective for high number of targets (&gt;20 targets)</li> <li>Low scalability due to increasing sample input requirements</li> </ul>